Keywords

• GDC-0199
• Venetoclax
• 1257044-40-8

Quick Details

• ProName: ABT-199 Supplier (CAS 1257044-40-8) P...
• CasNo: 1257044-40-8
• Molecular Formula: 868.44
• Appearance: yellow solid powder
• Application: Research and development in pharmaceut...
• PackAge: 1 gram/bag
• Port: shanghai
• ProductionCapacity: 1 Kilogram/Month
• Purity: >99%
• Storage: Please store the product under the rec...
• Transportation: by air or courier
• LimitNum: 1 Gram
• Heavy metal: N/A

Superiority

Rich Experience in produce;Competitive price
;Stable supply ability

Medi-tech Bioscientific Co., Ltd. is a supplier of inhibitors and intermediates used in drug discovery and pre-clinical development. We also have experienced contract labs and offer custom synthesis. Our credo is to provide the products and services with high quality and competitive prices.   
Quality 
        Medi-tech pays great attention to the purity, stability and activity of the products. Medi-tech provide chemical test data, such as HNMR, LC-MS and HPLC of each lot of products.   
Mission and vision 
        Medi-tech’s mission is to provide scientists worldwide an easy access to the most innovative life science reagents, and to help them accelerate their R&D development and make more significant discoveries. 
        Medi-tech’s vision is to be recognized by our clients as one of the best suppliers of inhibitors and intermediates for our superior quality, efficient and cost-effective services.

Details

ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1.
IC50 Value: <0.01 nM (Ki)
Target: Bcl-2 selective
ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.